– Exicure will reduce its workforce by approximately 50%, along with the implementation of other cost-cutting measures –
– Company to wind down immuno-oncology program cavrotolimod. | December 10, 2021
Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus -Exicure will reduce. | December 10, 2021
The R&D Dept.: Local patents for 12.16.20
Patent No. 10,858,331
The invention provides new aromatic aldehyde compounds that have greater potency in increasing the affinity of Hb for oxygen, greater potency for preventing sickling, and additional pharmacologic properties that ameliorate other symptoms of SCD. The invention further provides methods for treating SCD by providing a subject having SCD with a compound according to the invention.
Inventors:
Jurgen Venitz (Richmond),
Assignee: Virginia Commonwealth University (Richmond)
Dec. 8, 2020
Patent No. 10,858,163
Disclosed are package assemblies and methods of making the same, wherein the assemblies can include, among other elements, an outer carton defining an interior product storage compartment; an inner product support card slidably received within the product storage compartment; the inner support card having a main body portion and one or more flaps; and one or more primary product packages, each being secured to one o